CUR received notification that the US Patent and Trademark Office (USPTO) upholding the patentability, without amendment, Read more…
Optimism is the systematic tendency for people to be overly confident about the outcome of a potential event(s) but, have we forgotten the … what else(s).
British scientists have turned stem cells from spare IVF embryos into red blood cells as part of a project to manufacture synthetic blood on an industrial-scale. Read more…
Net loss for Q2/10 was $2.3 M or $0.06 per share on weighted average outstanding of 37.6 M common shares. Read more…
ACTC.OB is now positioned to obtain significant patents relating to cellular reprogramming and the generations of induced pluripotent stem (iPS) cells. Read more…
Net loss for Q4/10 was $5.1 M. or $0.18 per share. Read more…
CUR reported a Q2/10 net loss of $4.9 M or $0.12 per share with a 42.5 M weighted average of common shares outstanding. Read more…
Net loss to shareholders was $5.42 M and $0.11 per diluted loss per share.
Doctors in Italy announced they have used patients’ own stem cells to grow trachea tissue that led to seemingly successful transplanted windpipes
The worldwide market for hESCs is estimated at US$3.8 B in 2010. Growing at a robust CAGR of 24.8% during the period 2007-2015, the market is projected to reach US$10.7 B by 2015. While the global stem cell market is estimated to be $88.3 B by 2014, growing at a CAGR of 14.8 % from 2009 to 2014. Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.